Drug Trial News

RSS

NAVIGATOR trial: Nearly half of asthma patients improved with tezepelumab treatment

A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo, according to research published at the ATS 2022 international conference.

16 May 2022

Phase 1 clinical trial of vaccine for rare but deadly mosquito-borne viruses shows promising results

A vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV) was found to be safe, well-tolerated and induced a neutralizing antibody response in adult volunteers, according to newly published results from a Phase 1 clinical trial.

12 May 2022

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

A recent study published in the journal The Lancet summarized the final results of the Solidarity trial which aimed at finding out which drugs were most effective at reducing the severity of the disease among hospitalized patients.

9 May 2022

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

A new study published in the New England Journal of Medicine has discussed the efficacy and safety profile of the ZF2001 vaccine in adults, based on a randomized, placebo-controlled, multinational, double-blind phase 3 trial.

9 May 2022

Study finds promising new treatment for patients with behavioral variant frontotemporal dementia

A Monash University led study has found a promising new treatment for patients with behavioural variant frontotemporal dementia, the second most common form of dementia in the under 60s – resulting in a stabilising of what would normally be escalating behavioural issues, and a slowing of brain shrinkage due to the disease.

6 May 2022

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV).

6 May 2022

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early-stage Dupuytren's disease.

30 Apr 2022

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

29 Apr 2022

Phase I/II trials of new paratyphoid vaccine begin in Oxford

The University of Oxford in collaboration with the University of Maryland School of Medicine has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford - with first vaccinations taking place today (Tuesday).

26 Apr 2022

New COVID-19 vaccine proven to be safe and effective in late-stage clinical testing

A COVID-19 vaccine developed at the University of Washington School of Medicine has proven safe and effective in late-stage clinical testing.

25 Apr 2022

New data may change the standard of care for patients with advanced non-small cell lung cancer

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.

25 Apr 2022

Monoclonal-antibody combination AZD7442 prevents COVID-19

In a recent study published in The New England Journal of Medicine, the researchers examined the monoclonal-antibody combination AZD7442 to prevent coronavirus disease 2019 (COVID-19).

25 Apr 2022

New drug shows promise in treating a movement disorder associated with Huntington's disease

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

13 Apr 2022

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

A clinical study from Spain recently confirmed laboratory experiments made by researchers of Goethe University Frankfurt and University of Kent who showed that the protease inhibitor aprotinin prevented cells to be infected by SARS-CoV2.

12 Apr 2022

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Thousands more vulnerable people in England are now eligible to receive the UK's second oral antiviral treatment for Covid.

12 Apr 2022

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

Previous
1
...
33
34
35
36
37
38
39
...
1143
Next

Drug Trial News

NAVIGATOR trial: Nearly half of asthma patients improved with tezepelumab treatment

Phase 1 clinical trial of vaccine for rare but deadly mosquito-borne viruses shows promising results

Remdesivir shows no significant effect on patients with COVID-19 in Solidarity trial

ZF2001 vaccine safe and effective against symptomatic and severe-to-critical COVID

Study finds promising new treatment for patients with behavioral variant frontotemporal dementia

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

Phase I/II trials of new paratyphoid vaccine begin in Oxford

New COVID-19 vaccine proven to be safe and effective in late-stage clinical testing

New data may change the standard of care for patients with advanced non-small cell lung cancer

Monoclonal-antibody combination AZD7442 prevents COVID-19

New drug shows promise in treating a movement disorder associated with Huntington's disease

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

New study reveals oral opaganib's potent in vitro activity against Omicron

Nanocell COVID-19 vaccine elicits potent neutralizing response

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News